Golden Biotechnology Corp.’s new drug Antroquinonol ( Hocena ) was granted orphan drug designation by EC in Jan. 2017
European Commission has issued the Commission Implementing Decision that Antroquinonol is designated as an orphan medicinal product for the indication of treating pancreatic cancer and Antroquinonol shall be entered in the Community Register of Orphan Medicinal Products under number EU/3/16/1812.

In 2015 , Antroquinonol was granted orphan drug designation for treatment of pancreatic cancer by US FDA.